Back to today’s briefing

Story perspectives

Weight-Loss Drugs Face Price Critique Amid Access Calls

3/18/2025

28 5

Summary

Story summary

A recent study in JAMA Health Forum reveals that weight-loss drugs Zepbound and Wegovy, though effective, come with a hefty price tag, surpassing the $100,000-$150,000 per QALY threshold. This raises urgent calls for lower drug prices to ensure everyone can access these treatments, aligning with CMS's ongoing mission to reduce healthcare costs in the U.S.

1 of 1

Story summary

A recent study in JAMA Health Forum reveals that weight-loss drugs Zepbound and Wegovy, though effective, come with a hefty price tag, surpassing the $100,000-$150,000 per QALY threshold. This raises urgent calls for lower drug prices to ensure everyone can access these treatments, aligning with CMS's ongoing mission to reduce healthcare costs in the U.S.